Why is Telix Pharmaceuticals stock surging today?

Telix Pharmaceuticals' stock experienced a significant 10.3% increase, rising to A$18.03 on Tuesday following the U.S. FDA's approval of its cancer imaging drug, Pixclara (floretyrosine F 18). This approval marks a major milestone for the company, as it establishes Telix as the exclusive holder of an FDA-approved radiopharmaceutical imaging agent for identifying recurrent or progressive glioma, a type of brain tumor that accounts for 80% of all malignant brain tumors.

Gliomas represent about 30% of all brain and central nervous system tumors, underscoring the substantial commercial potential that the approval unlocks for Telix.

The company's management, including CEO Dr. Christian Behrenbruch and Precision Medicine CEO Kevin Richardson, were actively promoting the Pixclara approval and its wider pipeline at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15. This high-profile engagement with institutional investors provided Telix with a platform to directly communicate the significance of the FDA approval and the company's broader growth prospects.

Furthermore, Telix's recent financial performance has bolstered investor confidence. In the first half of 2026, the company reported group revenue of US$477 million, representing a 22% increase year-over-year. Adjusted EBITDA surged by an impressive 146%, and management has raised full-year guidance to exceed US$1 billion in total revenue and other income. These strong fundamentals have reinforced buyers' conviction in Telix's growth story.

With the ASX 200 index down 0.9% on Tuesday, Telix's stock price surge of 10.3% to A$18.03 demonstrated the market's positive reaction to the FDA approval and the company's robust financial performance.